Cargando…
The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. However, the pathways of either dopamine or its agonists that lead to the death of cells are incompletely understood and some are e...
Autores principales: | Liu, Xiaoshuang, Tang, Chao, Wen, Guodao, Zhong, Chunyu, Yang, Jin, Zhu, Junhao, Ma, Chiyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357924/ https://www.ncbi.nlm.nih.gov/pubmed/30740089 http://dx.doi.org/10.3389/fendo.2018.00768 |
Ejemplares similares
-
Are dopamine agonists still the first-choice treatment for prolactinoma in the era of endoscopy? A systematic review and meta-analysis
por: Cai, Xiangming, et al.
Publicado: (2022) -
Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists
por: Tang, Hao, et al.
Publicado: (2021) -
Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively
por: Tang, Chao, et al.
Publicado: (2019) -
Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases
por: Gonzaga, Maria de Fátima de Magalhães, et al.
Publicado: (2018) -
Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)